Wechselwirkungen · Viramune
Viramune 400 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 62
HOS-088301 · Präparat HOS-083615
Raltegravir No clinical data available. Due to Raltegravir and Viramune can be 400 mg BID the metabolic pathway of co-administered without dose raltegravir no interaction is adjustments. expected. ANTIBIOTICS Clarithromycin Clarithromycin AUC 0.69 Clarithromycin exposure was 500 mg BID (0.62-0.76) significantly decreased, 14-OH Clarithromycin Cmin 0.44 metabolite exposure increased. (0.30-0.64) Because the clarithromycin active Clarithromycin Cmax 0.77 metabolite has reduced activity (0.69-0.86) against Mycobacterium avium- intracellulare complex overall Metabolite 14-OH clarithromycin activity against the pathogen may AUC 1.42 (1.16-1.73) be altered. Alternatives to Metabolite 14-OH clarithromycin clarithromycin, such as Cmin 0 (0.68-1.49) azithromycin should be considered. Metabolite 14-OH clarithromycin Close monitoring for hepatic Cmax 1.47 (1.21-1.80) abnormalities is recommended
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): azithromycin (HOS-088112) clarithromycin (HOS-084517) raltegravir (HOS-086187)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-07T09:26:00Z · SHA-256 3124c3838448e2e235ceba5ac8568ac2aa499d31c735f56f78ff4d70c1cb2cc3 · Passage 576e0e48a042c2cc49eb62bbdc4d9ead770bba33c905227e72718e8576d86182 · Zeichen 13367–14823 im Abschnitt